Here are the S-1 registration statements from Electra Therapeutics, Inc. (ETRA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow ETRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ETRA filings page.
Electra Therapeutics, Inc. (ETRA), a late clinical-stage biopharmaceutical company developing SIRP-targeted precision medicines for immune‑mediated diseases and cancer, has filed an amended Form S-1 for its initial public offering of 21,666,667 shares of common stock, with an expected price range of $14.00 to $16.00 per share. The company has applied to list on the Nasdaq Global Select Market under the symbol ETRA and has granted underwriters a 30‑day option to purchase up to 3,250,000 additional shares.
Electra’s lead antibody, ipsoprubart, is in a global Phase 2/3 registrational program for secondary hemophagocytic lymphohistiocytosis (sHLH) and holds FDA Breakthrough Therapy and EMA PRIME designations. A second antibody, ELA822, has entered a Phase 1 trial in Europe for T‑cell mediated diseases. As of June 30, 2026, Electra reported $97.7 million in cash, cash equivalents and marketable securities and an accumulated deficit of $221.9 million; pro forma as adjusted for the offering, cash would be $394.3 million and stockholders’ equity $388.3 million.
The company is an emerging growth company and smaller reporting company, and its auditor’s report for 2025 includes a going concern explanatory paragraph. Electra has incurred recurring net losses (including $62.0 million in 2025) and expects to continue to incur significant losses as it advances clinical programs, indicating it will require substantial additional capital beyond this IPO over time.